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Abstract
Introduction: Occipital peripheral nerve stimulation is an interventional pain management therapy that provides
beneficial results in the treatment of refractory chronic occipital neuralgia. Herein we present a first-of-its-kind case
study of a patient with neurofibromatosis type 1 and bilateral occipital neuralgia treated with occipital peripheral
nerve stimulation.
Case presentation: A 42-year-old Caucasian woman presented with bilateral occipital neuralgia refractory to
various conventional treatments, and she was referred for possible treatment with occipital peripheral nerve
stimulation. She was found to be a suitable candidate for the procedure, and she underwent implantation of two
octapolar stimulating leads and a rechargeable, programmable, implantable generator. The intensity, severity, and
frequency of her symptoms resolved by more than 80%, but an infection developed at the implantation site two
months after the procedure that required explantation and reimplantation of new stimulating leads three months
later. To date she continues to experience symptom resolution of more than 60%.
Conclusion: These results demonstrate the significance of peripheral nerve stimulation in the management of
refractory occipital neuralgias in patients with neurofibromatosis type 1 and the possible role of neurofibromata in
the development of occipital neuralgia in these patients.
Introduction
Chronic daily headache (CDH) syndromes represent a
major health issue worldwide in terms of lost workdays
and revenue [1-3]. Diagnoses include migraine, atypical
migraine, cluster headaches, transformed migraines, cer-
vicogenic headaches, occipital and facial hemicranias, or
any combination of these diagnoses. Many of the
patients who experience these syndromes become totally
disabled after conservative and pharmacological treat-
ments fail to relieve their symptoms [4,5].
Occipital neuralgia is described by the National Insti-
tute of Neurological Diseases and Stroke as a “distinct
type of headache characterized by piercing, throbbing,
or electric-shock-like chronic pain in the upper neck,
back of the head, and behind the ears, usually on one
side” [6]. Typically, the pain of occipital neuralgia begins
at the base of the head and spreads upward within the
distribution of the greater and lesser occipital nerves.
Characteristically, it is neuropathic, with paroxysmal epi-
sodes of shooting electric shock-like symptoms.
Although the symptom etiology includes trauma, infec-
tion, and surgery, most patients with occipital neuralgia
have idiopathic etiologies of their pain [7].
N e u r o f i b r o m a t o s i st y p e1( N F - 1 )i sap o s s i b l eb u t
undocumented idiopathic etiology of occipital neuralgia.
This human genetic disease, which is caused by muta-
tions of the NF-1 tumor suppressor gene, has an inci-
dence of about one in every 2500 live births and has a
high rate of spontaneous mutations [8]. The characteris-
tic feature of NF-1 is neurofibromata, which are com-
plex lesions of the peripheral nervous system [8]. These
lesions are composed of abnormal local cells, including
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any medium, provided the original work is properly cited.Schwann cells, endothelial cells, fibroblasts, and a large
number of infiltrating inflammatory mast cells [8,9].
They can cause a variety of symptoms when they invade
surrounding tissues. Other characteristics of NF-1 are
flat, pigmented lesions of the skin (café au lait spots),
axillary freckles, pigmented iris hamartomas (Lisch
nodules), and a variety of central nervous system mani-
festations, such as optic nerve tumors, unidentified
bright objects in the visual field, and neurofibromas of
the spinal nerve roots (schwannomas) [10]. Although
headaches are very common in patients with NF-1, the
specific diagnosis of occipital neuralgia is not [11-13].
The initial treatment for both CDH syndromes and
occipital neuralgia is pharmacologic and is focused on
symptom relief [14]. Patients whose symptoms do not
respond to this initial therapy are treated secondarily
with occipital nerve blockade [15], radiofrequency abla-
tion [16], botulinum toxin A injections [17,18], surgical
decompression [19], and occipital peripheral nerve sti-
mulation (OPNS) [7,20-23]. OPNS involves the place-
ment of trial peripheral nerve-stimulating electrodes
over the occipital nerves. If the prerequisite dermatomal
paresthesia is achieved, then pain relief as a result of
permanent implantation has been reported to be as high
as 80% [7,20-23]. In this report, we present the case of a
woman with NF-1 and bilateral occipital neuralgia who
experienced pain relief after OPNS.
Case presentation
Patient history
A 42-year-old Caucasian woman was referred to our
hospital for pain management by a neurologist specializ-
ing in the treatment of daily headaches. She had experi-
enced daily intractable headaches since age 18 years.
She also had chronic bilateral occipital neuralgia on the
basis of the diagnostic criteria outlined in the second
edition of The International Classification of Headache
Disorders [24]. Her occipital neuralgia persisted for
more than 15 days monthly and was distributed
throughout the greater occipital nerves, beginning in the
occipital region and radiating upward to the top of the
head. When the occipital neuralgia occurred, her occipi-
tal area became very tender to palpation. Complete alle-
viation of her pain had been achieved for a limited time
with diagnostic bilateral greater occipital nerve blocks.
Her medical history included NF-1, which was first
diagnosed in childhood. Several neurofibromas had been
removed from her sacrum 10 years previously, as well as
many from her upper extremities. She also had had pro-
blems with depression, anxiety, alcohol consumption,
and smoking. She has been a housewife throughout her
adult life. With regard to her family medical history, her
mother had died at 68 years of age as a result of heart
disease, and her father was alive at 72 years of age with
a history of cancer. An older sister has rheumatoid
arthritis but not NF-1.
Before her referral to our service, she had undergone
extensive medical management with biofeedback train-
ing, physical therapy, massage, acupuncture, and phar-
macological management with narcotic and non-
narcotic pain medications. Her medications included
s u s t a i n e d - r e l e a s em o r p h i n e( 3 0m ge v e r y1 2h o u r s ) ,
hydrocodone and acetaminophen (10 mg and 325 mg,
respectively, every four to six hours), and pregabaline
(75 mg every eight hours). More recently, she had
undergone three greater occipital nerve blocks that
resulted in complete pain resolution that lasted from
two to three days. Because she required an ever-increas-
ing dose of morphine for pain relief, and because she
had responded to the occipital nerve blocks, she was
considered to be a good candidate for OPNS.
Trial procedure
At her baseline office visit, the patient underwent a dis-
ability and quality-of-life assessment by completing a
series of questionnaires (see “Quality-of-life assessment”
section below) and was found to be a suitable candidate
for a trial of OPNS. After the risks and benefits of the
procedure were discussed with the patient and her
informed consent was obtained, the trial of OPNS was
carried out in October 2008 by using two percutaneous
eight-contact leads (Octrode; St Jude Medical Neuromo-
dulation Division, Plano, TX, USA). After a week-long
successful trial with more than 80% symptom improve-
ment, the patient was deemed a suitable candidate for
permanent implantation and she underwent implanta-
tion of two permanent percutaneous eight-contact leads
(Octrode) and a conventional implantable pulse genera-
tor (IPG) (Genesis; St Jude Medical Neuromodulation
Division).
Permanent implantation procedure
On the day of the procedure, which was carried out in
an operating room, a slow intravenous infusion of 2 g of
cefazolin was started, and the patient was placed in a
prone position with pillows under her chest to augment
neck flexion. Monitored anesthesia was administered by
using intravenous fentanyl and midazolam at a level that
allowed the patient to be comfortable but able to inter-
act with medical personnel throughout the procedure.
The patient’s hair was shaved below a line connecting
the external occipital protuberance to the mastoid pro-
cesses, and her skin was treated with chlorhexidine. A
sterilely draped C-arm was introduced to obtain a true
anteroposterior image of the cervical spine at the C1-C2
interspace, and the overlying skin was marked with a
sterile marker. Thereafter a portable ultrasound with a
sterile linear array transducer of 5 MHz to 13 MHz
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occipital fossae and the bilateral greater occipital nerves
and arteries. The ultrasound probe was first placed at
the midline just below the external occipital protuber-
ance (Figure 1). The probe was slowly advanced laterally
at the same level until the greater occipital artery and
nerve were visualized as two distinct structures: the
artery as a hypoechogenic oval structure and the nerve
as a hyperechogenic structure (Figures 2 and 3). The
nerve could be traced from its exiting trunk into two
distinct divisions within the substance of the trapezious
muscle. The artery was identified by using Doppler
u l t r a s o u n d( F i g u r e2 ) .T h el o c a t i o n so ft h en e r v ea n d
t h ea r t e r yw e r em a r k e db i l a t e r a l l yo nt h es k i nw i t ha
sterile marker. The depths of both the artery and the
nerve were found to be consistent at 1.0 cm to 1.2 cm
from the skin surface. The skin overlying the greater
occipital protuberance was injected with 2 ml or 3 ml of
1% lidocaine as a local anesthetic, and the stimulating
electrodes were introduced through a 14-gauge introdu-
cer needle (0.5 cm to 0.7 cm below the skin surface) in
a mediolateral position. Positioning was guided by the
skin markings and was verified by fluoroscopy to com-
plement the ultrasonographic images (Figure 4). The
electrodes were tested intra-operatively by confirming
adequate dermatomal paresthesia within the occipital
nerve distribution. Implantation of the electrodes was
performed by creating a mid-line subcutaneous pocket
at the site of needle insertion. The implantable, pro-
grammable, rechargeable generator was permanently
implanted in a subcutaneous pocket area in the left but-
tock. For the implantation, a local anesthetic (0.25%
bupivacaine with epinephrine 1:200,000 to a total of 20
ml) was used for skin and tissue infiltration.
Re-implantation of the peripheral nerve-stimulating leads
Two months after the implantation procedure, she
developed an infection over the occipital implantation
area, and the leads and the IPG were removed (Figure
5). Bacterial cultures were not obtained during the
removal procedure. Her recovery from the procedure
was uneventful. After the infection resolved with anti-
biotic treatment, she underwent re-implantation of two
permanent octapolar leads and a new IPG (Eon Mini; St
Jude Medical Neuromodulation Division) in March 2009
without additional complications.
Quality-of-life assessment
The patient’s pain level and quality of life were assessed
at baseline and again at one, three, and six months after
implantation. The questionnaires used in these
Figure 1 An ultrasound image obtained with a linear
transducer placed over the greater occipital protuberance. The
anatomical layers are identified sonographically starting from the
surface and progressing toward the deeper layers.
Figure 2 An ultrasound image of the left occipital nerve as
well as two divisions of the greater occipital artery as they
pierce the substance of the trapezious muscle 1.0 cm to 1.2
cm from the skin.
Figure 3 A Doppler ultrasound image of the left occipital
nerve and artery as they pierce the substance of the trapezius
muscle side-by-side 1 cm from the skin.
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naire [25], the Visual Analogue Scale (VAS) [26], the
Oswestry Disability Questionnaire [27], and the SF-36
Health Survey [28]. The data gathered from these ques-
tionnaires were plotted for comparison. Qualitative data
were also collected from the patient’s medical record.
After the trial implantation, the patient experienced
nearly an 80% reduction in headache severity. Although
the initial implantation procedure was complicated by
infection in the implantation site and the patient under-
went reimplantation, she has experienced sustained ben-
efit from the treatment and remains infection-free. Over
time, the severity, frequency, and duration of her head-
aches have improved by more than 60%. She continued
to use hydrocodone and pregabaline, but was able to
discontinue use of morphine. All outcome measures of
pain and quality of life were positively affected by the
treatment. She reported improvement in her quality of
life, which she characterized as “being more active and
enjoying life,” being able to exercise, working for longer
hours, and having improved mood.
Discussion
Neurofibromatosis is an autosomal dominant, genetically
inherited disease first described in 1882 by the German
pathologist Friedrich Daniel von Recklinghausen. It
belongs to the family of phakomatoses and is subcate-
gorized into two types: NF-1 (von Recklinghausen’sd i s -
ease) and NF-2 (bilateral acoustic neurofibromatosis).
Our patient had classic NF-1, which is characterized
predominately by neurofibromas of the peripheral ner-
vous system [8].
According to the National Institutes of Health, a defi-
nitive diagnosis of NF-1 is made when two of seven car-
dinal clinical features of the disease are present [29]: (1)
six or more café au lait macules that measure >5 mm in
the greatest diameter in prepubertal individuals and >15
mm in the greatest diameter in postpubertal individuals;
(2) two or more neurofibromas of any type or one plexi-
form neurofibroma; (3) freckles in the axillary or ingu-
inal region; (4) optic nerve glioma; (5) two or more iris
hamartomas (Lisch nodules); (6) a distinctive osseous
lesion, such as sphenoid dysplasia or thinning of the
long-bone cortex with or without pseudoarthrosis; and
(7) a first-degree relative with NF-1 diagnosed on the
basis of the preceding six criteria.
There are many complications of NF-1, including
chronic hypertension, pheochromocytomas, brain
tumors, malignant peripheral nerve tumors, and a high
incidence of learning disabilities [10]. The most signifi-
cant complications are dermal and plexiform neurofi-
bromas, malignant peripheral nerve sheath tumors, and
other malignant tumors [10,11]. The known mechan-
isms by which tumor cells evade detection by the
human immune system are thought to play a role in the
progression to malignancy in patients with NF-1 [30].
Chronic headaches are among the most common neu-
rological manifestations of NF-1. In a hospital-based ser-
ies of 158 patients with NF-1 [11], headache was one of
the most common neurological manifestations. Twenty-
Figure 4 Placement of two octapolar stimulating array leads
over the bilateral occipital areas. Placement was carried out with
ultrasound guidance and fluoroscopy. The C1-C2 interspace, which
serves as a key fluoroscopic landmark for occipital peripheral nerve
stimulation, and the dens are easily identifiable.
Figure 5 Infected area over the site of the initial occipital
implantation at mid-line. Multiple neurofibromata are seen over
the patient’s back and neck area.
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idiopathic headaches and migraines. Although headaches
are common in patients with NF-1, the frequency has
varied between studies. In one study of 181 patients
with NF-1 [12], headache was present in 55 patients
(30%). This frequency was not statistically significantly
different from that found in the general population,
leading the study investigators to conclude that head-
ache is not a specific feature of NF-1. This conclusion,
however, was contradicted by the findings of another
study [13] that comprised 132 patients with NF-1.
Eighty-one (45%) of these patients were found to have
headaches, a frequency that led the study investigators
to conclude that patients with NF-1 are at greater risk
for headaches than the general population. Another
interesting finding of the study was that 38 (47%) of the
81 patients had recurrent headaches [13].
Although an association between NF-1 and distinct
neurological syndromes, such as the Arnold-Chiari I
malformation, has been reported [31], no association
has been found between NF-1 and occipital neuralgia.
The most common skull manifestations of NF-1 involve
the orbit, with very few reports of occipital defects in
patients with NF-1 [32]. Such occipital defects have
been found in a 54-year-old woman with a massive
plexiform neurofibroma that extended from the auricu-
lar region to the shoulder and was associated with large
left occipital and left petrous bone defects [32].
No neurofibromatous lesions were visualized sonogra-
phically during the placement of the stimulating leads in
our patient, but multiple small neurofibromata were
found during creation of the implant pocket at the pos-
terior neck site, and they were dissected. A subsequent
computed tomographic scan of her head revealed subcu-
taneous nodules in the tissue surrounding the stimulat-
ing leads in both occipital areas, which were consistent
with neurofibromas. The histological diagnosis of these
nodules is unknown, since the nodules were not sent for
pathological analysis. The clinical significance of these
nodules is also unknown, since they could interfere with
the surrounding branches of the greater and lesser occi-
pital nerves and create most of the symptomatology
reported by our patient.
Of interest is the fact that during ultrasound guidance
for OPNS, the greater occipital nerve was visualized
both medially (Figure 2) and laterally (Figure 3) to the
greater occipital artery. The variable course of the
greater occipital nerve as it relates to the greater occipi-
tal artery, as well as the ability of ultrasonography to
accurately identify both structures, makes a strong argu-
ment for the utilization of ultrasound guidance.
Only one other study has reported the use of neuro-
stimulation as a treatment for neurofibromatosis [11].
In that study, three patients who had headaches that
were refractory to conventional treatment were treated,
respectively, with cutaneous neurostimulation, spinal
cord neurostimulation, and cortical stimulation. Our
patient responded very well to OPNS, achieving an
80% reduction in symptoms initially and a persistent
>60% reduction at 10 months after electrode implanta-
tion. This outcome is in agreement with the outcomes
of OPNS in studies of patients without NF-1 and is
independent of the etiology of occipital neuralgia
[7,20-23].
Our patient’s recovery from implantation of the leads
was complicated with infection at the implantation site
approximately two months after the initial implantation.
It is unusual for any implant to become infected after
such a prolonged period and could possibly be a conse-
quence of NF-1, since patients with neurofibromatosis
are thought to be prone to infections because of a com-
promised immune system resulting from mast cell infil-
tration around neurofibromata [31].
Conclusion
In conclusion, we report the successful treatment of
chronic occipital neuralgia in a 42-year-old Caucasian
woman with NF-1. Additional case reports or case series
would give us a better understanding of the relationship
between occipital neuralgia and NF-1 as well as the effi-
cacy of OPNS in the treatment of occipital neuralgia in
patients with this genetic disorder.
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